Literature DB >> 22345182

Prognostic factors in patients after lobectomy for p-T1aN0M0 adenocarcinoma.

Hitoshi Igai1, Natsumi Matsuura, Shintaro Tarumi, Sung Soo Chang, Noriyuki Misaki, Shinya Ishikawa, Hiroyasu Yokomise.   

Abstract

OBJECTIVES: The seventh edition of the TNM Classification of Malignant Tumours was published in 2009. This study was conducted to investigate the prognostic factors of p-T1aN0M0 pulmonary adenocarcinoma, which is the earliest stage defined in the new TNM classification.
METHODS: We retrospectively studied 122 patients who underwent lobectomy at our institution for p-T1aN0M0 adenocarcinoma, as re-categorized in the seventh TNM classification. The patients were separated into groups on the basis of the following clinicopathologic parameters: age, < 70 vs. > 70 years; gender, male vs. female; preoperative serum carcinoembryonic antigen (CEA) level, < 5.0 vs. ≥ 5.0 ng/dl; tumour size, <10 vs. >10 mm; intratumoral vascular or lymphatic invasion, positive vs. negative. Univariate and multivariate analyses of disease-free survival were performed.
RESULTS: The median follow-up period was 41.4 months. Univariate analysis showed that prognostic factors such as age, CEA elevation and intratumoral vascular or lymphatic invasion were significant (age, < 70 vs. > 70 years; 97.1% vs. 82.0%, P = 0.0027; preoperative serum CEA level, < 5.0 vs. > 5.0 ng/dl; 93.3% vs. 33.3%, P < 0.0001; intratumoral vascular or lymphatic invasion, positive vs. negative; 31.3% vs. 96.5%, P < 0.0001). Multivariate analysis demonstrated that only intratumoral vascular or lymphatic invasion was a significantly independent prognostic factor (P = 0.0039, Hazard Ratio, 0.066; 95% Confidence Interval, 0.011-0.419).
CONCLUSIONS: Intratumoral vascular or lymphatic invasion should always be studied and included in the final pathology report in order to consider potential clinical and therapeutic relevance. The efficacy of adjuvant chemotherapy for these patients should also be evaluated in clinical trials.

Entities:  

Mesh:

Year:  2012        PMID: 22345182     DOI: 10.1093/ejcts/ezr006

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  5 in total

1.  Tumor Differentiation and EGFR Mutation Associated with Disease-Free Survival in Stage IA Lung Adenocarcinoma Patients with Curative Surgery.

Authors:  Lu Yang; Chong Pang; Fei Xu; Guangjian Yang; Haiyan Xu; Changli Wang; Yan Wang
Journal:  Cancer Manag Res       Date:  2020-12-07       Impact factor: 3.989

2.  Biomarker Potential of Preoperative Tumor Size in Determination of the Lymphovascular Invasion in Squamous Cell Lung Cancer and Lung Adenocarcinoma.

Authors:  Kemal Grbic; Aida Mujakovic; Orhan Lepara; Zahid Lepara; Edin Begic; Ferid Krupic
Journal:  Int J Appl Basic Med Res       Date:  2021-04-08

3.  Lymph but Not Blood Vessel Invasion Is Independent Prognostic in Lung Cancer Patients Treated by VATS-Lobectomy and Might Represent a Future Upstaging Factor for Early Stages.

Authors:  Melanie Biesinger; Nele Eicken; Alexander Varga; Michael Weber; Milos Brndiar; Georg Erd; Peter Errhalt; Klaus Hackner; Sarah Hintermair; Alexander Petter-Puchner; Axel Scheed; Elisabeth Stubenberger; Bahil Ghanim
Journal:  Cancers (Basel)       Date:  2022-04-08       Impact factor: 6.575

4.  Risk factors of recurrence for resected T1aN0M0 invasive lung adenocarcinoma: a clinicopathologic study of 177 patients.

Authors:  Fan Yang; Kezhong Chen; Yida Liao; Xiao Li; Kunkun Sun; Dongmei Bao; Jun Wang
Journal:  World J Surg Oncol       Date:  2014-09-13       Impact factor: 2.754

5.  The Significance of Serum Carcinoembryonic Antigen in Lung Adenocarcinoma.

Authors:  Jae Jun Kim; Kwanyong Hyun; Jae Kil Park; Seok Whan Moon
Journal:  Korean J Thorac Cardiovasc Surg       Date:  2015-10-05
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.